

## Louisiana Administrative Code

### Title 46 – Professional and Occupational Standards

#### Part LIII – Pharmacists

#### Chapter 5 – Pharmacists

#### §523. Collaborative Drug Therapy Management

- A. Definitions. As used in this Chapter, the following terms shall have the meaning ascribed to them in this Section:

*Board* – the Louisiana Board of Pharmacy.

*Collaborative Drug Therapy Management* or *Drug Therapy Management* – that practice in which a pharmacist, ~~to the extent authorized by a collaborative drug therapy management agreement,~~ voluntarily agrees with a physician ~~registered with the Louisiana State Board of Medical Examiners,~~ to manage the disease specific drug therapy of one or more patients of such physician, within a predetermined range of medication selected by the physician and set forth in a patient specific written ~~protocol or order set.~~ Drug therapy management shall be limited to:

- a. monitoring and modifying a disease specific drug therapy;
- b. collecting and reviewing patient history;
- c. obtaining and reviewing vital signs, including pulse, temperature, blood pressure, and respiration;
- d. ordering, evaluating, and applying the results of laboratory tests directly related to the disease specific drug therapy being managed under ~~written protocol~~ an order set, provided such tests do not require the pharmacist to interpret such testing or formulate a diagnosis;
- e. ~~administration of vaccines to a patient 16 years of age or older by a pharmacist authorized to administer vaccines by the board;~~
- f. ~~providing up to a single seven day supply of a single drug after all refills authorized on the original prescription issued to the patient by the patient's physician have been dispensed; and~~
- g. providing disease or condition specific patient education and counseling.

~~*Collaborative Drug Therapy Management Agreement* – a written document in which a pharmacist and a physician identify the terms and conditions under which they voluntarily agree to participate in collaborative drug therapy management.~~

*Controlled Substance* – any substance defined, enumerated, or included in federal or state statute or regulations, or any substance which may hereafter be designated as a controlled substance by amendment or supplementation of such statute or regulations.

*Disease Specific Drug Therapy* – a specific drug or drugs prescribed by a physician for a specific patient of such physician that is generally accepted within the standard of care for treatment of ~~one of~~ the following diseases or conditions:

- a. ~~treatment and prevention of arterial and venous clot propagation and disease, i.e., anti-coagulant therapy;~~
- b. ~~treatment and prevention of diabetes;~~
- e. ~~adjustment of medication administered by inhalant for treatment of asthma;~~
- d. ~~treatment and prevention of dyslipidemia;~~
- e. ~~smoking cessation therapy;~~
- f. ~~administration of disease specific vaccines to patients 16 years of age or older; and~~
- g. ~~such other drugs, diseases or conditions as may be subsequently recommended by the advisory committee and approved by the board.~~

*Drug* – (a) any substance recognized as a drug in the official compendium, or supplement thereto, designated by the board for use in the diagnosis, cure, mitigation, treatment or prevention of diseases in humans or animals; (b) any substance intended for use in the diagnosis, cure, mitigation, treatment or prevention of diseases in humans or other animals, or (c) any substance other than food intended to affect the structure or any function of the body of humans or other animals.

55 *Drugs of Concern* – a drug that is not a controlled substance but which is nevertheless defined and  
 56 identified in accordance with procedures established by the Louisiana Prescription Monitoring  
 57 Program Act, R.S. 40:1001-1014, as a drug with the potential for abuse.

58 *Pharmacist* – for purposes of this Section, an individual currently licensed by the board who has a  
 59 current unrestricted license to engage in the practice of pharmacy in the this state duly licensed by the  
 60 board, who is approved by the board to engage in collaborative practice for a specific disease or  
 61 condition based on the pharmacist's training and experience.

62 *Physician* – an individual lawfully entitled to engage in the practice of medicine in this state as  
 63 evidenced by a current, unrestricted license duly issued by the Louisiana State Board of Medical  
 64 Examiners.

65 *Prescribe* – a request or order transmitted in writing, orally, electronically or by other means of  
 66 telecommunication for a drug that is issued in good faith, in the usual course of professional practice  
 67 and for a legitimate medical purpose, by a physician for the purpose of correcting a physical, mental or  
 68 bodily ailment of his patient.

69 *Written Protocol Order Set* – a written set of directives or instructions containing each of the  
 70 components specified elsewhere in this Section for collaborative drug therapy management of disease  
 71 specific drug therapy for a specific patient. The ~~written protocol~~ order set shall be signed by the  
 72 physician and represents the physician orders for the collaborative drug therapy management to be  
 73 provided to the patient.

## 74 B. Registration

### 75 1. Eligibility

- 76 a. No pharmacist shall engage in collaborative drug therapy management in this state  
 77 until registered with the board in accordance with this Section. To be eligible for  
 78 registration, a pharmacist shall, as of the date of the application:
- 79 i. possess a current, unrestricted license to practice pharmacy issued by the  
 80 board and not be the subject of a pending investigation or complaint by the  
 81 board or by the pharmacy licensing authority of any other state or  
 82 jurisdiction;
  - 83 ii. be actively engaged in the practice of pharmacy in this state and the  
 84 provision of pharmacist care similar to the activities anticipated in the  
 85 collaborative drug therapy management agreement.
- 86 b. A pharmacist shall be deemed ineligible for registration of collaborative drug  
 87 therapy management who:
- 88 i. does not possess the qualifications prescribed by §523.B.1.a;
  - 89 ii. has voluntarily surrendered or had suspended, revoked, or restricted his  
 90 controlled dangerous substances license, permit, or registration (state or  
 91 federal);
  - 92 iii. has had a pharmacy license suspended, revoked, placed on probation or  
 93 restricted in any manner by the board or by the pharmacy licensing  
 94 authority of any other state or jurisdiction;
  - 95 iv. has had an application for pharmacist licensure rejected or denied; or
  - 96 v. has been, or is currently in the process of being denied, terminated,  
 97 suspended, refused, limited, placed on probation or under other  
 98 disciplinary action with respect to participation in any private, state, or  
 99 federal health insurance program.
- 100 c. The board may, in its discretion, waive the limitations referenced in Subparagraph  
 101 B.1.b of this Section on a case-by-case basis.
- 102 d. The board may deny registration to an otherwise eligible pharmacist for any of the  
 103 causes enumerated in R.S. 37:1241.A, or any other violation of the provisions of  
 104 the Pharmacy Practice Act or the board's rules.
- 105 e. The burden of satisfying the board as to the eligibility of a pharmacist for  
 106 registration to engage in collaborative drug therapy management shall be upon the  
 107 pharmacist. A pharmacist shall not be deemed to possess such qualifications  
 108 unless and until the pharmacist demonstrates and evidences such qualifications in  
 109 the manner prescribed by and to the satisfaction of the board.  
 110  
 111

- 112                   2. Application and Issuance
- 113                   a. Application for registration to engage in collaborative drug therapy management
- 114                   shall be made upon forms supplied by the board. Application forms and
- 115                   instructions may be obtained from the board's website at [www.labp.com](http://www.labp.com)
- 116                   [www.pharmacy.la.gov](http://www.pharmacy.la.gov) or by contacting the board's office.
- 117                   b. An application for registration to engage in collaborative drug therapy
- 118                   management shall include:
- 119                   i. the pharmacist's full name, license number, mailing address of record,
- 120                   and emergency contact information;
- 121                   ii. a description of the pharmacist's professional education that qualifies him
- 122                   to engage in collaborative drug therapy management activities described
- 123                   in the agreement;
- 124                   iii. proof documented in a form satisfactory to the board that the pharmacist
- 125                   possesses the qualifications set forth in this Section;
- 126                   ~~iv. a fully executed copy of a collaborative drug therapy management~~
- 127                   ~~agreement conforming to the requirements of this Section;~~
- 128                   ~~v. confirmation the pharmacist shall only engage in collaborative drug~~
- 129                   ~~therapy management to the extent detailed in the agreement and in~~
- 130                   ~~accordance with the rules of the board; and~~
- 131                   vi. such other information and documentation as the board may require to
- 132                   evidence qualification for registration.
- 133                   c. The board may reject or refuse to consider any application for registration which is
- 134                   not complete in every detail required by the board ~~or may refuse to consider a~~
- 135                   ~~collaborative drug therapy management agreement which fails to comply with the~~
- 136                   ~~minimum requirements of this Section.~~ The board may, in its discretion, require a
- 137                   more detailed or complete response to any request for information set forth in the
- 138                   application as a condition to consideration.
- 139                   d. A pharmacist seeking registration to engage in collaborative drug therapy
- 140                   management shall be required to appear before the board or its designee if the
- 141                   board has questions concerning the nature or scope of the pharmacist's application,
- 142                   finds discrepancies in the application, or for other good cause as determined by the
- 143                   board.
- 144                   e. When all the qualifications, requirements, and procedures of this Section are met
- 145                   to the satisfaction of the board, the board shall approve and register a pharmacist to
- 146                   engage in collaborative drug therapy management. Registration of authority to
- 147                   engage in collaborative drug therapy management shall not be effective until the
- 148                   pharmacist receives notification of approval from the board.
- 149                   f. Although a pharmacist shall notify the board each time he intends to engage in
- 150                   collaborative drug therapy management with a physician other than the physician
- 151                   identified in the pharmacist's original application, registration with the board is
- 152                   only required once. The board shall maintain a list of pharmacists who are
- 153                   registered to engage in collaborative drug therapy management.
- 154                   g. Each pharmacist registered to engage in collaborative drug therapy management
- 155                   shall be responsible for updating the board within 10 days in the event of any
- 156                   change in the information recorded in the original application.
- 157                   3. Expiration of Registration; Renewal
- 158                   a. A pharmacist's registration to engage in collaborative drug therapy management
- 159                   with a physician shall terminate and become void, null and without effect upon the
- 160                   earlier of:
- 161                   i. death of either the pharmacist or physician;
- 162                   ii. loss of license of either the pharmacist or physician;
- 163                   iii. disciplinary action limiting the ability of either the pharmacist or the
- 164                   physician to enter into collaborative drug therapy management;
- 165                   iv. notification to the board that either the pharmacist or physician has
- 166                   withdrawn from collaborative drug therapy management;
- 167                   v. a finding by the board of any of the causes that would render a pharmacist
- 168                   ineligible for registration; or

- 169 vi. expiration of a pharmacist's license or registration to engage in  
 170 collaborative drug therapy management for failure to timely renew such  
 171 license or registration.
- 172 b. Registration of authority to engage in collaborative drug therapy management shall  
 173 expire annually on the same day as a pharmacist's license unless renewed by the  
 174 pharmacist by submitting an application to the board upon forms supplied by the  
 175 board, together with verification of the accuracy of registration ~~and collaborative~~  
 176 ~~drug therapy management agreement information~~ on file with the board. An  
 177 application for registration renewal shall be made part of and/or accompany a  
 178 pharmacist's renewal application for pharmacist licensure.
- 179 c. The timely submission of an application for renewal of registration shall operate to  
 180 continue the expiring registration in effect pending renewal of registration or other  
 181 final action by the board on such application for renewal.
- 182 C. Advisory Committee. The Collaborative Drug Therapy Management Advisory Committee, constituted  
 183 as provided for in LAC 46:XLV.7417, shall assist the Board of Medical Examiners and the Board of  
 184 Pharmacy on matters relative to collaborative drug therapy management. The President of the Board  
 185 of Pharmacy shall appoint a pharmacist to serve on the committee, and said pharmacist shall serve at  
 186 the pleasure of the Board of Pharmacy.
- 187 D. Standards of Practice
- 188 1. Authority, Responsibility, and Limitations of Collaborative Drug Therapy Management
- 189 a. A pharmacist registered with the board under this Section may engage in  
 190 collaborative drug therapy management with a physician:  
 191 ~~i. to the extent authorized by a collaborative drug therapy management~~  
 192 ~~agreement filed with and approved by the board; and~~  
 193 ii. in accordance with a patient specific, drug specific, disease specific  
 194 ~~written protocol order set~~, satisfying the requirements of this Section.
- 195 b. A pharmacist engaged in collaborative drug therapy management shall:  
 196 i. retain professional responsibility to his patient for the management of ~~his~~  
 197 their drug therapy;  
 198 ii. establish and maintain a pharmacist-patient relationship with each patient  
 199 subject to ~~the collaborative drug therapy management agreement~~;  
 200 iii. be geographically located to be physically present to provide pharmacist  
 201 care to a patient subject to collaborative drug therapy management;  
 202 iv. provide on a scheduled ~~defined in the written protocol~~ basis no less than  
 203 every three months, a ~~periodic~~ status report on the patient, including but  
 204 not limited to, any problem, complication, or other issues relating to  
 205 patient non-compliance with drug therapy management. This  
 206 requirement may be met by entering the information in the patient's  
 207 medical record.; and  
 208 v. be available through direct telecommunication for consultation,  
 209 assistance, and direction.
- 210 c. A pharmacist's registration to engage in collaborative drug therapy management  
 211 with a physician is personal to the pharmacist. A ~~registered~~ pharmacist registered  
 212 to engage in drug therapy management shall not allow another pharmacist not so  
 213 registered or any other individual to exercise the authority conferred by such  
 214 registration. ~~A registered pharmacist shall not engage in collaborative drug~~  
 215 ~~therapy management with a non-physician or with any physician who is not a party~~  
 216 ~~to the pharmacist's collaborative drug therapy management agreement on file with~~  
 217 ~~the board.~~
- 218 d. Collaborative drug therapy management shall only be utilized for ~~those conditions~~  
 219 ~~or diseases identified in, and in the manner specified by, this Section. Additional~~  
 220 ~~conditions or diseases for which there are generally accepted standards of care for~~  
 221 ~~disease specific drug therapy may be identified by the advisory committee and~~  
 222 ~~approved by the board.~~ *Disease Specific Drug Therapy* as defined in this Section.
- 223 e. ~~Only a pharmacist who holds the academic degree of Doctor of Pharmacy, which~~  
 224 ~~degree provided specific training in the area of anti-coagulant drug therapy, shall~~  
 225 ~~engage in collaborative drug therapy management in such particular area of~~

226 practice covered by a collaborative drug therapy management agreement. The  
 227 board may, in its discretion, grant an exception to this limitation on a case by case  
 228 basis to a pharmacist who does not possess the academic degree required by this  
 229 Section upon the affirmative recommendation and advice of the advisory  
 230 committee that the pharmacist possesses the equivalent or other acceptable  
 231 advanced training in the area of practice covered by the agreement.

- 232 f. The scope of the collaborative drug therapy management shall not include:
- 233 i. any patient of the physician for whom such physician has not prepared a  
 234 patient specific, drug specific, disease or condition specific written  
 235 protocol order set based on a face-to-face visit with the patient;
  - 236 ii. ~~drug therapy management of more than one specific disease or condition.~~  
 237 ~~Administration of a vaccine or smoking cessation therapy are excepted~~  
 238 ~~from this provision.~~
  - 239 iii. ~~drug therapy management of any patient by more than one registered~~  
 240 ~~physician and one pharmacist;~~
  - 241 iv. ~~any patient under the age of 18 years of age. Administration of a vaccine~~  
 242 ~~or smoking cessation therapy are excepted from this provision.~~
  - 243 v. ~~pregnant or nursing mothers;~~
  - 244 vi. initiation or discontinuance of drug therapy by a pharmacist, except as  
 245 specified in the written protocol order set;
  - 246 vii. the management of controlled substances or drugs of concern; or
  - 247 viii. substitution of a drug prescribed by a physician without the explicit  
 248 written consent of such physician.

## 249 2. Informed Consent

- 250 a. A pharmacist shall not engage in collaborative drug therapy management of a  
 251 patient without the patient's written informed consent.
- 252 b. In addition to the requirements provided by law for obtaining a patient's informed  
 253 consent, each patient who is subject to a collaborative drug therapy management  
 254 ~~agreement~~ shall be:
  - 255 i. informed of the collaborative nature of drug therapy management for the  
 256 patient's specific medical disease or condition and provided instructions  
 257 and contact information for follow-up visits with the pharmacist and  
 258 physician;
  - 259 ii. informed he may decline to participate in a collaborative drug therapy  
 260 management practice and may withdraw at any time without terminating  
 261 the physician-patient or pharmacist-patient relationship; and
  - 262 iii. provided written disclosure of any contractual or financial arrangement  
 263 with any other party that may impact one of the party's decision to  
 264 participate in the agreement.
- 265 c. All services provided ~~pursuant to a collaborative drug therapy management~~  
 266 ~~agreement shall be consistent with the agreement~~ and shall be performed in a  
 267 setting which insures patient privacy and confidentiality.

## 268 3. Collaborative Drug Therapy Management Agreement

- 269 a. A collaborative drug therapy management agreement shall, at a minimum, include:
  - 270 i. ~~the name, professional license number, address or addresses,~~  
 271 ~~telephone/cell phone number, e-mail address, and emergency contact~~  
 272 ~~information for the pharmacist and physician, and the date of signing and~~  
 273 ~~termination of the agreement;~~
  - 274 ii. ~~a description of the manner and circumstances under which the~~  
 275 ~~pharmacist and physician shall engage in collaborative drug therapy~~  
 276 ~~management;~~
  - 277 iii. ~~the condition or disease to be managed;~~
  - 278 iv. ~~the specific drug or drugs to be utilized for such condition or disease;~~
  - 279 v. ~~the drug therapy management activities, as defined in this Section, to be~~  
 280 ~~performed by the pharmacist as authorized by the physician;~~

- 281 vi. ~~the procedure to be followed by the parties for drug therapy management~~  
 282 ~~and a plan of accountability defining the respective responsibilities of the~~  
 283 ~~pharmacist and physician;~~  
 284 vii. ~~a plan for reporting and documenting drug therapy management activities~~  
 285 ~~in the pharmacy and medical records and schedule by which such are to~~  
 286 ~~take place. A pharmacist shall submit a report to the collaborating~~  
 287 ~~physician at least every 30 days, or more frequently if warranted by~~  
 288 ~~clinical conditions, regarding the status of a patient's collaborative drug~~  
 289 ~~therapy management, with such report made a part of the pharmacy~~  
 290 ~~record for such patient;~~  
 291 viii. ~~a plan for record keeping, record sharing, and record storage. The~~  
 292 ~~agreement shall acknowledge all collaborative drug therapy management~~  
 293 ~~records shall be treated as and governed by the laws applicable to~~  
 294 ~~physician medical records;~~  
 295 ix. ~~acknowledgement each patient subject to the agreement shall be notified~~  
 296 ~~that a collaborative drug therapy management agreement exists, describes~~  
 297 ~~the procedures for obtaining informed consent of such patient, and the~~  
 298 ~~plan to address patient needs when both the pharmacist and physician are~~  
 299 ~~absent from the practice setting; and~~  
 300 x. ~~the procedure and schedule for reviewing and assessing the quality of~~  
 301 ~~care provided to each patient subject to collaborative drug therapy~~  
 302 ~~management under written protocol.~~  
 303 b. ~~In the event the physician authorizes the pharmacist to order, evaluate, and apply~~  
 304 ~~the results of a laboratory test or tests directly related to disease specific drug~~  
 305 ~~therapy being managed under written protocol, the agreement shall identify the~~  
 306 ~~specific test or tests and describe the plan for securing such testing.~~  
 307 c. ~~The agreement shall affirm that:~~  
 308 i. ~~collaborative drug therapy management shall be in conformity with~~  
 309 ~~generally accepted standards of care for treatment of a patient's specific~~  
 310 ~~disease or condition;~~  
 311 ii. ~~all services provided pursuant to a collaborative drug therapy~~  
 312 ~~management shall be consistent with the agreement and performed in a~~  
 313 ~~setting that insures patient privacy and confidentiality; and~~  
 314 iii. ~~a copy of the agreement shall be maintained on-site by the respective~~  
 315 ~~parties.~~  
 316 d. ~~The agreement may include the identity of one back up pharmacist possessing the~~  
 317 ~~qualifications for collaborative drug therapy management required by this Section,~~  
 318 ~~who shall serve in the absence of the registered pharmacist to the agreement. The~~  
 319 ~~identifying information specified in this Section shall be provided for such~~  
 320 ~~pharmacist, along with an acknowledgement of responsibility to adhere to the~~  
 321 ~~same obligations and commitments imposed on the registered pharmacist to the~~  
 322 ~~agreement, as evidenced by a dated signature.~~  
 323 e. ~~An agreement is valid for a period of time not to exceed one year. A collaborating~~  
 324 ~~pharmacist shall insure that a collaborative drug therapy management agreement is~~  
 325 ~~annually reviewed, updated as appropriate, and signed by the pharmacist and~~  
 326 ~~physician.~~  
 327 f. ~~Each registered pharmacist is responsible for updating the board within 10 days in~~  
 328 ~~the event any of the information required and submitted in accordance with this~~  
 329 ~~Section changes after the board has approved the agreement.~~  
 330 4. Written Protocols Order Sets  
 331 a. A separate protocol order set shall be written for each patient to be managed by  
 332 collaborative drug therapy management. A copy of each written protocol order set  
 333 shall be:  
 334 i. provided to the collaborating physician and pharmacist; and  
 335 ii. made part of the patient's pharmacy record.; and  
 336 iv. ~~appended by the pharmacist to the collaborative drug therapy~~  
 337 ~~management agreement with the physician and maintained in a separate~~

- 338 file at the pharmacist's practice site listed on the pharmacist's registration  
 339 on file with the board.
- 340 b. A physician shall develop a patient specific ~~written protocol~~ order set for a  
 341 particular patient or utilize a standard written protocol order set, incorporating  
 342 what patient specific deviations, if any, the physician may deem necessary or  
 343 appropriate for such patient. In either event, an ~~written protocol~~ order set for  
 344 disease specific drug therapy shall adhere to generally accepted standards of care  
 345 and shall identify, at a minimum:
- 346 i. the pharmacist, the physician, and telephone number and other contact  
 347 information for each;
  - 348 ii. the patient's name, address, gender, date of birth, and telephone number;
  - 349 iii. the disease or condition to be managed;
  - 350 iv. the disease specific drug or drugs to be utilized;
  - 351 v. the type and extent of drug therapy management the physician authorizes  
 352 the pharmacist to perform;
  - 353 vi. the specific responsibilities of the pharmacist and physician;
  - 354 vii. the procedures, criteria, or plan the pharmacist is required to follow in  
 355 connection with drug therapy management;
  - 356 viii. the specific laboratory test or tests, if any, directly related to drug therapy  
 357 management the physician authorizes the pharmacist to order and  
 358 evaluate;
  - 359 ix. the reporting and documentation requirements of the pharmacist and  
 360 physician respecting the patient and schedule by which such are to take  
 361 place;
  - 362 x. the conditions and events upon which the pharmacist and physician are  
 363 required to notify one another; and
  - 364 xi. procedures to accommodate immediate consultation by telephone or  
 365 direct telecommunication with, between, or among the pharmacist,  
 366 physician, and the patient.
- 367 c. Each ~~written protocol~~ order set utilized for collaborative drug therapy management  
 368 of a patient shall be reviewed annually by the collaborating ~~pharmacist~~ physician,  
 369 or more frequently as such ~~pharmacist~~ physician deems necessary, to address  
 370 patient needs and to insure compliance with the requirements of this Section. A  
 371 ~~collaborating pharmacist's~~ The physician's signature and date of review shall be  
 372 noted on the ~~written protocol~~ order set and maintained by the pharmacist in  
 373 accordance with this Section.

#### 374 5.—Administration of Vaccines

- 375 a. ~~A collaborative drug therapy management agreement which includes the~~  
 376 ~~administration by a pharmacist of a patient specific order for administration of a~~  
 377 ~~disease specific vaccine shall include documentation of the pharmacist's authority~~  
 378 ~~to administer such medications, pursuant to §521 of the board's rules.~~
- 379 b. ~~In addition to the requirements of this Section, the following information shall be~~  
 380 ~~included in any written protocol for any patient receiving a vaccination from a~~  
 381 ~~collaborating pharmacist:~~
  - 382 i. ~~the identity of the drug, dose, and route of administration;~~
  - 383 ii. ~~the date of the original order and the date of any authorized subsequent~~  
 384 ~~dose or administration;~~
  - 385 iii. ~~a statement the patient or patient's tutor, curator, or legal guardian~~  
 386 ~~shall be provided the manufacturer's vaccine information statement with~~  
 387 ~~each dose;~~
  - 388 iv. ~~confirmation written policies and procedures for disposal of used or~~  
 389 ~~contaminated supplies shall be utilized;~~
  - 390 v. ~~a requirement for the pharmacist to immediately report any adverse event~~  
 391 ~~to the collaborating physician and such governmental entities as may be~~  
 392 ~~directed or required by the Louisiana Department of Health and~~  
 393 ~~Hospitals; and~~

- 394 vi. ~~confirmation the physician shall be promptly available for consultation~~  
 395 ~~regarding contraindications and adverse reactions in said physician's~~  
 396 ~~patient.~~
- 397 c. ~~This Section shall not prevent or restrict the Louisiana Department of Health and~~  
 398 ~~Hospitals, Office of Public Health, or any other governmental entity of this state~~  
 399 ~~from administering vaccines under the authority of other laws of this state.~~
- 400 6. ~~Additional Refills. Whether or not and the extent to which a collaborating physician may~~  
 401 ~~authorize a collaborating pharmacist to dispense up to a single seven day supply of a single~~  
 402 ~~drug for a single patient utilized for disease specific drug therapy after all refills authorized~~  
 403 ~~for such physician's patient have been dispensed, shall be specifically included in the~~  
 404 ~~collaborative drug therapy management agreement with such pharmacist, as well as the~~  
 405 ~~written protocol applicable to a specific patient.~~
- 406 7. Reporting Obligations and Responsibilities
- 407 a. A pharmacist engaged in collaborative drug therapy management shall ~~notify the~~  
 408 ~~board, in writing, within 10 days of the occurrence or discovery of:~~ report  
 409 annually, as a condition to the renewal of his registration, whether or not and the  
 410 extent to which the pharmacist is engaged in collaborative drug therapy  
 411 management and such other information as the board may request; and
- 412 i. ~~the death of a patient which was, in the pharmacist's opinion, directly~~  
 413 ~~related to drug therapy management;~~
- 414 ii. ~~complications or errors which are, in the pharmacist's opinion, directly~~  
 415 ~~related to drug therapy management;~~
- 416 iii. ~~a pharmacist's termination of a collaborative drug therapy management~~  
 417 ~~agreement with a physician and applicable reasons;~~
- 418 iv. ~~a physician's termination of a collaborative drug therapy management~~  
 419 ~~agreement with a pharmacist and applicable reasons;~~
- 420 v. ~~a patient's election to withdraw from participation in collaborative drug~~  
 421 ~~therapy management and applicable reasons;~~
- 422 vi. ~~his or a physician's failure or refusal to abide by the terms, conditions, or~~  
 423 ~~restrictions of a collaborative drug therapy management agreement or~~  
 424 ~~written protocol and applicable reasons;~~
- 425 vii. ~~the pharmacist's retirement or withdrawal from active practice in this~~  
 426 ~~state or relocation to another state to engage in pharmacy practice; or~~
- 427 viii. ~~the revocation, suspension, or other restriction imposed on a physician's~~  
 428 ~~license which would prohibit the physician from entering into a~~  
 429 ~~collaborative drug therapy management agreement.~~
- 430 b. A pharmacist engaged in collaborative drug therapy management shall comply  
 431 with reasonable requests by the board for personal appearances or information  
 432 relative to the functions, activities, and performance of a pharmacist or physician  
 433 engaged in collaborative drug therapy management.
- 434 8. Records
- 435 a. The following information shall be included in the pharmacy's record of a patient  
 436 subject to collaborative drug therapy management:
- 437 i. the prescription or order implementing collaborative drug therapy  
 438 management;
- 439 ii. the ~~written protocol~~ order set applicable to the patient evidencing  
 440 documentation of the physician's annual review;
- 441 iii. documentation of all activities performed by the pharmacist;
- 442 iv. consultations and status reports by and between the pharmacist and  
 443 physician; and
- 444 v. documentation of the patient's informed consent to collaborative drug  
 445 therapy management.
- 446 b. A pharmacist registered to engage in collaborative drug therapy management shall  
 447 maintain and produce, upon inspection conducted by or at the request of a  
 448 representative of the board, a copy of any ~~or all collaborative drug therapy~~  
 449 ~~management agreements, amendments thereto, applicable written protocols~~ order  
 450 sets and such other records or documentation as may be requested by the board to

451 assess a pharmacist's compliance with requirements of this Section, the Pharmacy  
452 Practice Act, or other applicable board rules.

453 E. Sanctions

- 454 1. Action against Registration. For noncompliance with any of the provisions of this Section,  
455 the board may, in addition to or in lieu of administrative proceedings against a pharmacist's  
456 license, suspend or revoke a pharmacist's registration to engage in collaborative drug therapy  
457 management, or may impose such terms, conditions, or restrictions thereon as the board may  
458 deem necessary or appropriate.
- 459 2. Action against Pharmacist License. Any violation or failure to comply with the provisions of  
460 this Section shall be deemed a violation of R.S. 37:1241.A.1, as well as a violation of any  
461 other applicable provisions of R.S. 37:1241.A, providing cause for the board to take any of  
462 the actions permitted in R.S. 37:1241.A against the pharmacist's license.
- 463 3. Unauthorized Practice. Nothing in this Section shall be construed as authorizing a pharmacist  
464 to issue prescriptions, exercise independent medical judgment, render diagnoses, provide  
465 treatment, assume independent responsibility for patient care, or otherwise engage in the  
466 practice of medicine as defined in the Louisiana Medical Practice Act. Any person who  
467 engages in such activities, in the absence of medical licensure issued by the Louisiana State  
468 Board of Medical Examiners, shall be engaged in the unauthorized practice of medicine and  
469 subject to the penalties prescribed by the Louisiana Medical Practice Act.

470

471 AUTHORITY NOTE: Promulgated in accordance with R.S. 37:1164(37)(b)(i).

472 HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1125  
473 (June 2007), amended LR

474